Wednesday, March 5, 2008
MicroRNA Mimicry: Not All Triggers are Created Equal
With regards to microRNA mimicry as a therapeutic in general, this and an increasing number of other studies reporting on the post-transcriptional regulation of microRNA/small RNA function, including subcellular localization, the sorting into different small RNA effector complexes, and microRNA/small RNA maturation, however also raise the question about the critical role of the choice of the right microRNA mimic in order to achieve the desired therapeutic effect.
This may be a real problem if one assumed that in order to obtain the therapeutic benefit such a microRNA mimick would have to regulate more or less the same set of target genes as its endogenous counterpart. The introduction of a synthetic siRNA-like microRNA duplex e.g. may not sufficiently recapitulate the normal sorting mechanism if this was linked to its biogenesis. Moreover, such a synthetic small RNA would likely have to be modified for pharmacological reasons, something we know may profoundly affect, and ideally reduce the off-target spectrum of an siRNA, but in the case of a microRNA mimick may be undesirable. It is also becoming increasingly clear that even a small difference in the level of a microRNA may have profound effects on its biological output.
While this represents significant scientific challenges and calls for the use of optimal models of human disease as part of the pre-clinical validation process, it also represents IP opportunities for the increasing number of microRNA therapeutics companies. It will be interesting to see whether such companies will soon try to differentiate themselves based on the specific chemistry of microRNA mimicry or a particular gene therapy approach. More so than for RNAi Therapeutics, gene therapy may enjoy here a number of unique advantages, and it would make sense for companies like Benitec, Oxford Biomedia, or Nucleonics to consider a microRNA therapeutics program.
[see also my blog on microRNA sponges for a gene therapy approach to inhibiting microRNA function]
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.